

Disclaimer	
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arisen from or in reliance upon the whole or any part of the contents of this announcement.	
Cash Dividend Announcement for Equity Issuer	
Issuer name	EuroEyes International Eye Clinic Limited
Stock code	01846
Multi-counter stock code and currency	Not applicable
Other related stock code(s) and name(s)	Not applicable
Title of announcement	Interim Dividend for the six months ended 30 June 2023
Announcement date	29 August 2023
Status	New announcement
Information relating to the dividend	
Dividend type	Interim (Semi-annual)
Dividend nature	Ordinary
For the financial year end	31 December 2023
Reporting period end for the dividend declared	30 June 2023
Dividend declared	HKD 0.0511 per share
Date of shareholders' approval	Not applicable
Information relating to Hong Kong share register	
Default currency and amount in which the dividend will be paid	HKD 0.0511 per share
Exchange rate	HKD 1 : HKD 1
Ex-dividend date	11 September 2023
Latest time to lodge transfer documents for registration with share registrar for determining entitlement to the dividend	12 September 2023 16:30
Book close period	From 13 September 2023 to 14 September 2023
Record date	14 September 2023
Payment date	28 September 2023
Share registrar and its address	Tricor Investor Services Limited
	17/F, Far East Finance Centre
	16 Harcourt Road
	Hong Kong
Information relating to withholding tax	
Details of withholding tax applied to the dividend declared	Not applicable

Information relating to listed warrants / convertible securities issued by the issuer	
Details of listed warrants / convertible securities issued by the issuer	Not applicable
Other information	
Other information	Not applicable
Directors of the issuer	
As at the date of this announcement, the board of directors comprises Dr. Jørn Slot Jørgensen, Dr. Markus Braun, Mr. Jannik Jonas Slot Jørgensen and Professor Dan Zoltan Reinstein as executive directors; Mr. Marcus Huascar Bracklo as non-executive director; and Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive directors.	